✦ LIBER ✦

Growth Inhibition of CD20-positive B Lymphoma Cell Lines by IDEC-C2B8 Anti-CD20 Monoclonal Antibody

✍ Scribed by Taji, Hirohumi ;Kagami, Yoshitoyo ;Okada, Yasutaka ;Andou, Manabu ;Nishi, Yoshimi ;Saito, Hidehiko ;Seto, Masao ;Morishima, Yasuo

Book ID: 108581647
Publisher: Wiley (Blackwell Publishing)
Year: 1998
Tongue: English
Weight: 469 KB
Volume: 89
Category: Article
ISSN: 0910-5050
DOI: 10.1111/j.1349-7006.1998.tb03280.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioimmunotherapy of B-cell lymphoma wi

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

✍ R. O. Dillman 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 104 KB

Mechanism of action on B cell lymphoma b

Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody

✍ Oyama, T; Kagami, Y; Seto, M; Morishima, Y 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 68 KB

Monoclonal Antibody Therapy for B-Cell L

Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan

✍ Kensei Tobinai 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 276 KB

Treatment of B-cell non-Hodgkin's lympho

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have

Treatment of radiation-relapsing primary

Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody

✍ M. E. Lacouture; J. M. Baron; A. B Jani; A. E Laumann; K Soltani 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

Successful Treatment With a Chimeric Ant

Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody

✍ Takahiro Maeda; Yasuaki Yamada; Masayuki Tawara; Reishi Yamasaki; Yuichi Yakata; 📂 Article 📅 2001 🏛 Carden Jennings Publishing 🌐 English ⚖ 188 KB